

899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002

June 4, 2020

8:30 am

OPEN SESSION AGENDA
(VIA ZOOM MEETING DUE TO THE COVID-19 PUBLIC HEALTH EMERGENCY)

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

CALL TO ORDER:

PRESIDING:

BOARD MEMBERSHIP/ATTENDANCE:

BOARD MEMBERS:		
	DR . TAMARA McCANTS, PHARM.D. R.PH CHAIRPERSON	
	DR. BENJAMIN MILES, PHARM.D. R.PH	
	MR. ALAN FRIEDMAN, R.PH	
	DR. ASHLEE BOW, PHARM.D. R.PH	
	DR. ALLISON HILL, PHARM.D. R.PH	
	CHIKITA SANDERS, CONSUMER BOARD MEMBER	
	GREGORY CENDANA, CONSUMER MEMBER	
STAFF:	SHAUNA WHITE, EXECUTIVE DIRECTOR	
	KARIN BARRON, HEALTH LICENSING SPECIALIST	
	LUANNE GREENAWAY, PROGRAM SPECIALIST	
	COUNTEE GILLIAM, BOARD INVESTIGATOR	
LEGAL STAFF:	CARLA WILLIAMS, ASSISTANT GENERAL COUNSEL	
VISITORS:		

Open Session Agenda

Quorum:

Introduction:		
o6o4-O-01	<p><u>Approval of the Open Session Meeting Minutes</u></p> <p>(a) April 15, 2020 (b) May 7, 2020</p>	
<u>Consent Agenda</u>	None	
<u>Executive Director Report</u>	<p><u>Licensing Report</u></p> <ul style="list-style-type: none"> ➤ Statistical Report on pharmacy professionals in the District of Columbia ➤ Prescription Monitoring Program Update ➤ Opioid Strategic Plan 	Dr. Shauna White
<u>Assistant General Counsel Report</u>		Ms. Carla Williams
o6o4-O-02	<u>Status Update on the Rulemaking Adding Continuing Education Requirements in Public Health Priorities-Verbal Report</u>	
o6o4-O-03	<p><u>Pharmacist COVID-19 Testing Emergency Regulations</u></p> <p>Emergency Regulations</p>	
<u>Subcommittee Reports</u>		
o6o4-O-04	<p><u>Legislative and Regulatory Subcommittee Report</u></p> <p>Collaborative Practice Agreement Regulations with Nurse Practitioners</p>	Mr. Alan Friedman
o6o4-O-05	<p><u>Re-Visit DC Board of Pharmacy Bylaws</u></p> <p>(a) Bylaws</p>	
<u>Matters of Consideration</u>		
o6o4-O-06	<p><u>MPJE Retake Policy Clarification</u></p> <p>(a) MPJE Retake Policy</p>	
o6o4-O-07	<u>Vote on the Next Percentage of Pharmaceutical Detailers to Audit Continuing Education</u>	

o604-O-o8	<u>Communications Subcommittee Report</u>	
NABP E-Newsletter	<p><u>May 26, 2020</u></p> <p>FDA Updates Guidance Documents on Compounding For Hospitalized Patients During the COVID-19 Pandemic</p> <p>Over 6,800 Applications Received for NABP Passport, a Service Supporting Boards' COVID-19 Response</p> <p>List of Antibody Tests Being Removed From FDA's 'Notification List'</p> <p>\$225 Million Approved for COVID-19 Testing in Rural Communities, HHS Reports</p> <p>FDA, FTC Issue Warning Letters to Two Amazon Associated Companies Selling Fake COVID-19 Treatments</p> <p><u>May 21, 2020</u></p> <p>FDA Issues Updated Guidance for Compounding Pharmacies Experiencing PPE Shortages</p> <p>FDA Shares Recommendations With Providers About Antibody Tests for COVID-19</p> <p>COVID-19 Pandemic May Lead to New Complications in the Opioid Crisis</p> <p>FDA Warns About Possible Accuracy Issues With Certain COVID-19 Tests</p> <p>FDA, FTC Take Additional Action Against Companies Selling Fraudulent COVID-19 Treatments</p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/.</p>	Dr. Tamara McCants
<u>Public Comments</u>		
Motion to Adjourn the Open Session	<p>"Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)." (Roll Call Vote)</p>	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at _:_

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.